Read the Technology Feature by SCIENCE about “Big data, big picture: Metabolomics meets systems biology” in which companies and scientists explain how they use metabolomics to understand system biology.
VIB’s Technology Watch team has been active for almost a decade, continuously analyzing the potential of emerging technologies and mediating researchers’ access to them. By expanding VIB’s network of technology suppliers, purchasing licenses and negotiating business partnerships, the Tech Watch team enables VIB scientists to have privileged access to cutting-edge scientific innovations. One example comes in the form of a powerful lipidomics research tool made available to VIB scientists through a collaboration with Lipotype, a Max-Planck spin-off and key service provider. Since 2015, Lipotype technology has been a crucial factor in several major breakthroughs in multiple life sciences domains.
The largest lipidomics study to date analyzing skin lipids in more than 250 skin samples has been published in “Scientific Reports” (Sadowski T. et al. “Large-scale human skin lipidomics by quantitative, high-throughput shotgun mass spectrometry.” Scientific Reports 2017, doi: 10.1038/srep43761). The study applied a novel Skin Lipidomics Technology Platform developed by Lipotype GmbH, a German Max-Planck-Institute spin-off.
Two publications of researchers at the Flanders Institute of Biotechnology (VIB) with Lipotype lipidomicsFebruary 10, 2017
An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease
with Lipotype as project partner
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership funded by the Innovative Medicines Initiative (IMI), member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland has announced the launch of a 5-year project (total budget 28.9 Million Euro) with the aim to improve prevention and management of Diabetes Kidney Disease (DKD).
In the latest issue of the Journal of the American Heart Association, Lipotype and Lund University published a paper in which high-throughput lipidomic screening was successfully applied to reveal molecular lipid profiles in blood serum specific for Diabetes mellitus and myocardial infarction.
Berlin/Dresden, 4 November 2016: Kai Simons, founding director of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) and managing director of Lipotype GmbH, receives the Robert Koch Medal in Gold for his lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the lipid raft concept. The Award Ceremony takes place on Friday, November 4th 2016 at the Berlin-Brandenburg Academy of Sciences and Humanities.
Lipotype GmbH, a German Max-Planck spin-off company, launched its novel Lipotype Shotgun Skin Lipidomics Technology and offers lipid analysis services for applications such as cosmetic claim support, topical drug development, efficacy testing for dermatological pharmacology and the cosmetic industry.
Professor Kai Simons, Founding Director of the Max-Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG) and Founder/CEO of Lipotype GmbH receives the Robert Koch Medal in Gold for his impressive lifetime achievements, in particular for his characterization of membrane-forming lipids and the development of the Lipid Raft Model.